MedTrace Logo

Myocardial Fibrosis and Inflammation in Liver Cirrhosis

NCT05047029 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 13

Last updated 2021-09-16

No results posted yet for this study

Summary

The aim of this clinical prospective study is to assess structural and functional myocardial changes in patients with liver cirrhosis after implantation of transjugular intrahepatic portosystemic shunt (TIPS).

Conditions

  • Cirrhosis, Liver
  • Cardiomyopathies
  • Portal Hypertension

Interventions

PROCEDURE

Transjugular intrahepatic portosystemic shunt implantation

Transjugular intrahepatic portosystemic shunt is an artificial channel within the liver that establishes communication between the inflow portal vein and the outflow hepatic vein. It is used to treat portal hypertension (e.g., in liver cirrhosis)

DIAGNOSTIC_TEST

Magnetic resonance imaging

Multiparametric cardiac and hepatic magnetic resonance imaging

Sponsors & Collaborators

  • University Hospital, Bonn

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-02
Primary Completion
2021-01-05
Completion
2021-09-08

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05047029 on ClinicalTrials.gov